| 03.05 |
DURECT Corporation And Endo Pharmaceuticals Sign Agreement
to Develop And Commercialize DURECT’s Seven-Day Transdermal Pain Patch |
| 02.05 |
DURECT Initiates Phase II Program for Its Sufentanil Patch Product |
| 02.05 |
DURECT Completes Dosing of the Phase I Pharmacokinetic Study
for Its Sufentanil Patch Product and of the First Cohort
of the Phase II Study for Its Post-Operative Pain Relief Depot |
| 01.05 |
DURECT Corporation Announces Completion of Clinical Trial
Enrollment for DURIN™-Based Leuprolide Product Candidate |
| 12.04 |
DURECT Corporation Announces Initiation of Phase III Studies for
Remoxy, a Novel Oral Pain Medication using the ORADUR™ Gel-Cap |
| 12.04 |
DURECT and Voyager Pharmaceutical Announce the Acceptance
of DURINTM Investigational New Drug Application and Clinical Protocol
by the FDA for the Treatment of Alzheimer’s Disease |
| 10.04 |
DURECT Initiates Phase II Clinical Program for Post-Operative Pain Relief Depot |
| 10.04 |
DURECT Initiates Phase I Trial for Its Proprietary Transdermal Sufentanil Patch |
| 07.04 |
DURECT Announces Positive Clinical Results
with its ORADURTM Sustained Release Oral Gel-cap Technology |
| 06.04 |
DURECT Corporation and NeuroSystec Corporation Announce Exclusive
Agreement to Develop Treatments for Certain Inner Ear Disorders Including Tinnitus |
